TKIs inhibiting ABC transporters were able to reverse the MDR phenotype of cancer cells and enhance the effect of other anticancer drugs at the quite low, usually noncytotoxic concentrations achieved in patients [13,20,56]. Here, ABCG2 is linked to cancer.